Biofactura Awarded $67.4 Million to Develop Smallpox Biodefense Therapeutic

BioFactura, Inc. announced on September 26th a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox.  This product has the potential to fulfill an unmet need in preparedness for a second anti-viral therapeutic with a different mechanism of action to the current stockpile to guard against potential host resistance.

Variola Virus (VARV), the causative agent for smallpox infections in humans, can become resistant to treatment suggesting that the best medical countermeasure approach would utilize complementary therapeutics.  To fill the need for additional treatment options, BioFactura, in partnership with BARDA, is advancing the development of its monoclonal antibody-based Smallpox Biodefense Therapeutic in a stepwise approach building upon years of early product research and development and a strong foundation of cell line, process, analytical and manufacturing development experience and expertise.

Dr. Darryl Sampey, President and CEO of BioFactura, stated, “This advanced research and development contract award marks the culmination of decades of discovery and development work performed by our team, our partners at the National Institutes of Health and our principal government collaborator Dr. Jay Hooper at the U.S. Army Research Institute of Infectious Diseases.  We look forward to working with BARDA in this new chapter of product development as we bring an important defense to our citizens.”

“This government contract for the development of a novel smallpox therapeutic countermeasure is the result of years of cutting edge biotechnology research, the perseverance of forward-thinking scientific entrepreneurs, the risk appetite of loyal investors, and the dedication of the Department of HHS/BARDA to maintain the safety and security of the United States population,” stated Dr. Jeffrey Hausfeld, BioFactura’s Chief Medical Officer and Chairman. “It is truly an evolving American success story and one which as a physician and Chairman of the Board of BioFactura, I am proud to be a part of.”

Tags: CBRNe, Protection, Biological, Contract

Our Current Sponsors

  • Flir
  • BioFire Defense
  • Federal Resources
  • Cristanini
  • Airboss
  • Flir
  • Tex Shield
  • Argon
  • 908 Devices
  • Avon
  • Flir
  • Battelle
  • Bw Tek
  • CQC
  • Decon Seven Systems
  • Flir
  • DQE
  • Dxterity
  • First Line Technology
  • Futurtech
  • Flir
  • Metrohm Raman
  • NBC sys
  • Proengin
  • Qinetiq
  • Flir
  • Tex Shield
  • Wl Gore
  • ADS, Inc.
  • Rigaku Analytical Devices
  • Flir
  • Paul Boye Technologies
  • Observis
  • Zeteo Tech
  • Bertin Instruments
  • ECOTEST
  • Tex Shield